This event has passed. View key highlights below.
At the 2023 American Society for Pharmacology and Experimental Therapeutics (ASPET) Annual Meeting, Xyzagen presented new research on CPL-01, a novel extended-release formulation of ropivacaine, in support of Cali Biosciences. The meeting, held May 6–10, 2023 in St. Louis, Missouri, brought together researchers and drug developers focused on advances in pharmacology and translational science.
The presentation highlighted CPL-01 as a sustained-release local anesthetic designed to address key limitations of existing long-acting pain therapies used in post-surgical settings.
Scientific Focus
The study, titled “CPL-01, A Novel Extended-Release Ropivacaine, Demonstrates Consistent and Predictable Systemic Exposure Compared to Liposomal Bupivacaine in Multiple Surgical Models,” emphasized the consistent and predictable pharmacokinetic profile of CPL-01 across several surgical models.
These findings address common challenges associated with current long-acting local anesthetics, including variability in drug release and systemic exposure—factors that can limit clinical adoption. The data suggest CPL-01 may offer improved PK control while maintaining sustained analgesic coverage.
Presentation Details
Poster Title: CPL-01, A Novel Extended-Release Ropivacaine, Demonstrates Consistent and Predictable Systemic Exposure Compared to Liposomal Bupivacaine in Multiple Surgical Models
Session: Poster Session 2.145
Presentation Date: May 8, 2023
Authors: Stevie Pope, Christopher Crean, Sarah Thrasher, PJ Chen, Lee Chen, DeeDee Hu, and Erol Onel
Final Takeaways
This work reflects Xyzagen’s experience supporting extended-release formulation programs through integrated pharmacokinetics and translational analysis. By generating clear, decision-enabling PK data, Xyzagen helps sponsors evaluate differentiated drug delivery approaches in pain management and beyond.
If you’re developing extended-release or long-acting formulations and need support with pharmacokinetics or translational strategy, contact Xyzagen to learn how we can help.
About Xyzagen, Inc.
Xyzagen augments a client’s pharmacology and pharmacokinetics drug development team. As a leading pharmacokinetics consultancy and contract research organization with wet lab and rodent vivarium facilities, Xyzagen accelerates early-phase drug development through its proprietary First-in-Rat® and First-in-Mouse® discovery platforms. The company also supports late-stage clinical pharmacokinetics, population PK modeling, and quantitative medicine. Xyzagen’s boutique structure ensures personalized, expert collaboration with small clients during critical stages of drug development, from candidate selection to pre-NDA meetings.
Media Contact:
Christopher Crean
Founder & CEO
Xyzagen, Inc.
Phone: 919-726-2072
Email: [email protected]
